Robert Shorr, Ph.D, D.I.C, Chief Executive Officer of Cornerstone Pharmaceuticals, talks about his company’s approach to the treatment of cancer by targeting and exploiting specific metabolic pathways with the goal of achieving a tremendous advance in cancer treatment.
About Cornerstone Pharmaceuticals:
Cornerstone Pharmaceuticals is a privately held pharmaceutical company uniquely focused on the discovery and development of innovative cancer therapies that exploit the metabolic pathways that are common to different cancer types but different from normal cells and tissues.
Summary:
Cornerstone Pharmaceuticals has identified a new class of compounds. These compounds are taken up very selectively into cancer cells and become highly concentrated in the mitochondria resulting in cancer specific cell death.
Dr. Shorr has disclosed the following:
Salary: Cornerstone Pharmaceuticals
Royalty: Cornerstone Pharmaceuticals
Receipt of Intellectual Property Rights/Patent Holder: Cornerstone Pharmaceuticals
Consulting Fees: Brainstorm, Metabolics, CNS Pharma
Ownership Interest: Cornerstone Pharmaceuticals
